

Donald A. Robinson
Keith J. Miller
Justin T. Quinn
ROBINSON MILLER LLC
One Newark Center, 19th Floor
Newark, New Jersey 07102
(973) 690-5400 (Telephone)
(973) 466-2760 (Facsimile)

*Attorneys for Plaintiffs BTG International Ltd.,
Janssen Biotech, Inc., Janssen Oncology, Inc., and
Janssen Research & Development, LLC.*

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

BTG INTERNATIONAL LIMITED, et al.

Plaintiffs,

v.

AMNEAL PHARMACEUTICALS LLC,
et al.

Defendants.

BTG INTERNATIONAL LIMITED, et al.,
Plaintiffs,

v.

AMERIGEN PHARMACEUTICALS, INC.,
and
AMERIGEN PHARMACEUTICALS LTD.,

Defendants.

)
) Honorable Kevin McNulty, U.S.D.J.
)
) Civil Action No.: 2:15-cv-5909 (KM) (JBC)
)
)

) **Oral Argument Requested**
)

) Return Date: March 5, 2018
)
)

)
) Honorable Kevin McNulty, U.S.D.J.
)
) Civil Action No.: 2:16-cv-2449 (KM) (JBC)
)
)

**NOTICE OF PLAINTIFFS' MOTION *IN LIMINE* PURSUANT TO 35 U.S.C. § 315(e)(2)
TO PRECLUDE PRIOR ART-BASED INVALIDITY DEFENSES**

TO: ALL COUNSEL OF RECORD

PLEASE TAKE NOTICE that, on March 5, 2018, or as soon thereafter as the Court deems appropriate, Plaintiffs Janssen Biotech, Inc., Janssen Oncology, Inc., Janssen Research & Development, LLC, and BTG International Ltd. shall move before the Honorable Kevin McNulty, at the Marin Luther King, Jr. Federal Building and Courthouse in Newark, New Jersey, for an Order granting their Motion *in Limine* Pursuant to 35 U.S.C. § 315(e)(2) to Preclude Prior Art-Based Invalidity Defenses, which seeks to preclude Defendants Amerigen Pharmaceuticals Ltd., Amerigen Pharmaceuticals Inc. (“Amerigen”); Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC (“Amneal”); Dr. Reddy’s Laboratories, Inc., Dr. Reddy’s Laboratories Ltd. (“DRL”); Mylan Pharmaceuticals Inc., Mylan Inc. (“Mylan”); Teva Pharmaceuticals USA, Inc. (“Teva”); West-Ward Pharmaceuticals Corp., Hikma Pharmaceuticals, LLC (“West-Ward”); Wockhardt Bio AG, Wockhardt USA, LLC, and Wockhardt Ltd. (“Wockhardt”) (collectively, “Defendants”) from presenting prior art-based invalidity defenses at trial pursuant to 35 U.S.C. § 315(e)(2).

PLEASE TAKE FURTHER NOTICE that in support of their motion, Plaintiffs will rely on the accompanying Brief, the Declaration of Andrew T. Langford and exhibits thereto, which are submitted herewith; and Plaintiffs’ reply papers, if any. A proposed form of Order has been submitted simultaneously with this motion.

PLEASE TAKE FURTHER NOTICE that oral argument is requested.

Dated: February 7, 2018

Respectfully submitted,

s/ Keith J. Miller

Keith J. Miller (kmiller@rwmlegal.com)

Donald A. Robinson

(drobinson@rwmlegal.com)

Justin T. Quinn (jquinn@rwmlegal.com)

ROBINSON MILLER LLC

One Newark Center, 19th Floor

Newark, New Jersey 07102

(973) 690-5400 (Telephone)

(973) 466-2760 (Facsimile)

*Attorneys for Plaintiffs BTG International
Ltd., Janssen Biotech, Inc., Janssen
Oncology, Inc. and Janssen Research &
Development, LLC*

Of Counsel:

*Attorneys for Plaintiffs Janssen Biotech, Inc.,
Janssen Oncology, Inc. and
Janssen Research & Development, LLC*

David T. Pritikin (dpritikin@sidley.com)

SIDLEY AUSTIN LLP

1. S. Dearborn Street

Chicago, Illinois 60603

Tel: (312) 853-7000

Fax: (312) 853-7036

Bindu Donovan (bdonovan@sidley.com)

Todd L. Krause (tkrause@sidley.com)

S. Isaac Olson (iolson@sidley.com)

Alyssa B. Monsen (amonsen@sidley.com)

SIDLEY AUSTIN LLP

787 Seventh Avenue

New York, New York 10019

Tel: (212) 839-5300

Fax: (212) 839-5599

Andrew Langford (alangford@sidley.com)

SIDLEY AUSTIN LLP

2021 McKinney Avenue

Attorneys for Plaintiff BTG International Ltd.

Anthony C. Tridico

(anthony.tridico@finnegan.com)

Jennifer H. Roscetti

(jennifer.roschetti@finnegan.com)

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, LLP

901 New York Avenue, N.W.

Washington D.C. 20001

Tel: (202) 408-4000

Fax: (202) 408-4400

Suite 2000
Dallas, TX 75201
Tel: (214) 981-3300
Fax: (214) 981-3400

CERTIFICATE OF SERVICE

I hereby certify that on February 7, 2018, copies of the foregoing Notice of Motion and supporting documents were served by electronic mail upon all counsel of record.

Dated: February 7, 2018

s/ Keith J. Miller
Keith J. Miller